Nation & World News

Postpartum depression: FDA approves new, fast-acting drug

By Debbie Lord, Cox Media Group National Content Desk
March 20, 2019

The U.S. Food and Drug Administration has, for the first time, approved a drug to fight postpartum depression.

On Tuesday, the agency announced the approval of brexanolone, a synthetic form of a hormone produced by progesterone in the brain.

Brexanolone is believed to help ease depression and anxiety by dampening neural activity, Dr. Samantha Meltzer-Brody, director of the perinatal psychiatry program at the University of North Carolina at Chapel Hill, told The New York Times.

It was approved after clinical trials showed it was quickly effective in women who suffer crippling depression as new mothers.

One in 9 new mothers will suffer from postpartum depression, according to the Centers for Disease Control and Prevention.

"Postpartum depression is a serious condition that, when severe, can be life-threatening. Women may experience thoughts about harming themselves or harming their child," said Tiffany Farchione, acting director of the Division of Psychiatry Products in the FDA's Center for Drug Evaluation and Research, who was quoted in a press release.

Here’s what to know about Zulresso

Symptoms of postpartum depression

From the Mayo Clinic, here is a list of symptoms of postpartum depression:

About the Author

Debbie Lord, Cox Media Group National Content Desk

More Stories